Last €48.61 EUR
Change Today -0.01 / -0.02%
Volume 81.8K
As of 11:39 AM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

orpea (ORP) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/2/14 - €49.75
52 Week Low
04/29/13 - €31.22
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ORPEA (ORP)

Related News

No related news articles were found.

orpea (ORP) Related Businessweek News

No Related Businessweek News Found

orpea (ORP) Details

ORPEA Société Anonyme operates long-term health care, post-acute care, and rehabilitation and psychiatric care facilities. It operates through two segments, France and International. The company operates nursing homes and long-term care facilities in France, Belgium, Italy, and Spain; post-acute and rehabilitation care facilities in France; and general psychiatric clinics in France, Italy, and Switzerland. Its care facilities provide care and support services to residents; and logistical and residential services, such as accommodation, meals, laundry, room cleaning, and various entertainment activities. The company’s multi-disciplinary post-acute and rehabilitation care facilities offer physical medicine and physical therapy; orthopaedic and trauma rehabilitation; haematology and oncology post-acute and rehabilitation care; geriatric post-acute and rehabilitation care; and other specialist services, such as care of chronic neurovegetative states and multi-functional medical services. Its psychiatric clinics provide services for the patients with acute mental pathologies, such as mood disorders, anxiety disorders, addiction, overuse or burn-out syndromes, chronic fatigue syndrome, fibromyalgia, sleep disorders, eating disorders, borderline personality disorders, age-related psychiatric disorders, and certain psychotic disorders. As of March 1, 2013, the company had a network of 431 healthcare facilities with 40,374 beds in Europe. ORPEA Société Anonyme was founded in 1989 and is headquartered in Puteaux, France.

Founded in 1989

orpea (ORP) Top Compensated Officers

Chief Executive Officer, Chief Financial Offi...
Total Annual Compensation: €1.1M
Chief Operating Officer, Deputy Chief Executi...
Total Annual Compensation: €605.0K
Compensation as of Fiscal Year 2012.

orpea (ORP) Key Developments

ORPEA Proposes Dividend for the Financial Year of 2013

ORPEA announced that its Board of Directors will propose paying out a dividend of EUR 0.70 per share in respect of the 2013 financial year, compared with EUR 0.60 in respect of the previous financial year at the Annual General Meeting on 25 June 2014.

ORPEA Société Anonyme Announces Consolidated Financial Results for the Financial Year to December 31, 2013

ORPEA Société Anonyme announced consolidated financial results for the financial year to December 31, 2013. For the year, the company reported revenues of €1,607.9 million against €1,429.3 million a year ago. EBITDAR (EBITDA before rents) was €433.2 million against €370.1 million a year ago. EBITDA was €298.0 million against €257.9 million a year ago. Recurring operating profit was €227.3 million against €194.4 million a year ago. Operating profit was €267.5 million against €221.3 million a year ago. Profit before tax was €177.3 million against €148.5 million a year ago. Profit attributable net profit was €116.9 million against €97.0 million a year ago. Net debt stood at €1,742 million, €122 million below its level at 30 June 2013.

ORPEA Société Anonyme Reports Sales Results for the Fourth Quarter and Year Ended December 31, 2013; Provides Revenue Guidance for 2014

ORPEA Société Anonyme reported sales results for the fourth quarter and year ended December 31, 2013. For the quarter, the company reported total sales of EUR 418.7 million compared to EUR 378.0 million reported a year ago. For the year, the company reported total sales of EUR 1,608.1 million compared to EUR 1,429.3 million reported a year ago. Revenue raised 12.5%, ahead of the EUR 1,600 million target announced in November 2012. This solid performance is the result of ORPEA's effective growth model, which combines: selective acquisitions, which have come mainly outside France in the last two years; ongoing strong organic growth, which amounted to 7.1% in 2013 and represented additional revenue of EUR 100 million. Mature facilities have high occupancy rates, and the 1,900 beds it added in 2013 are rapidly filling up. This organic growth momentum is also the result of aggressive focus on quality over the last 25 years, which enables it to enhance the appeal of ORPEA facilities on an ongoing basis. This performance will be accompanied by solid growth in earnings and cash flow, together with controlled, optimised debt levels following the various financial transactions in 2013. In 2014, the company is targeting revenue of EUR 1,770 million, up 10.1% or EUR 162 million relative to 2013, with organic growth remaining solid. This target only reflects growth that is already secure, and excludes any further acquisitions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ORP:FP €48.61 EUR -0.01

ORP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Korian-Medica €27.19 EUR -0.05
Le Noble Age €16.97 EUR +0.07
View Industry Companies

Industry Analysis


Industry Average

Valuation ORP Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 14.5x
TEV/Sales -- Not Meaningful

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORPEA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at